3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Cystitis, Interstitial
1
Breast Neoplasms
1
Arthralgia
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
11
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
Radiotherapy
5
dodecyl maltoside
4
apaziquone
4
tislelizumab
3
Cystoscopy
3
ALT-803
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
monalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
Chondroitin Sulfates
×
Clear all
NCT07495072
2026-03-27
PRO-GAG
BLAD-HYA Group
Phase NA
Recruiting
56 enrolled